Calamos Advisors
GHDX

Calamos Advisors’s Genomic Health, Inc. GHDX Stock Holding History

Calamos Advisors’s Portfolio GHDX Stock Details GHDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-5,840
Closed -$409K – 804
2019
Q1 		$409K Hold
5,840
– – ﹤0.01% 620
2018
Q4 		$376K Hold
5,840
– – ﹤0.01% 604
2018
Q3 		$410K Buy
+5,840
New +$342K ﹤0.01% 616

Other funds holding GHDX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Calamos Advisors's GHDX Position: Q2 2019 in Review

Calamos Advisors sold out of Genomic Health, Inc. (GHDX) in Q2 2019, closing a stake of 5,840 shares — an estimated $409K sold.

Calamos Advisors first reported a position in GHDX in Q3 2018 and held it in 3 quarters. The position peaked at $410K in Q3 2018. 215 funds tracked by Wall St. Rank hold GHDX as of Q2 2019.

  • Calamos Advisors reported no remaining Genomic Health, Inc. position as of Q2 2019 after selling out during the quarter.
  • Calamos Advisors sold 5,840 Genomic Health, Inc. shares in Q2 2019, an estimated $409K.
  • Calamos Advisors first reported a position in Genomic Health, Inc. in Q3 2018 and held it in 3 quarters.
  • Calamos Advisors's Genomic Health, Inc. position peaked at $410K in Q3 2018.
  • 215 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q2 2019.

Based on Calamos Advisors's 13F filing for Q2 2019, filed 7 Aug 2019.